Experimental Workflow for Preclinical Studies of Human Antifibrotic Therapies

Lien Reolizo; Michitaka Matsuda; Ekihiro Seki

doi:10.1007/978-1-0716-3207-9_18

Experimental Workflow for Preclinical Studies of Human Antifibrotic Therapies

Methods Mol Biol. 2023:2669:285-306. doi: 10.1007/978-1-0716-3207-9_18.

Authors

Lien Reolizo¹, Michitaka Matsuda¹, Ekihiro Seki^{2

3}

Affiliations

¹ Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Ekihiro.Seki@cshs.org.
³ Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Ekihiro.Seki@cshs.org.

PMID: 37247068
DOI: 10.1007/978-1-0716-3207-9_18

Abstract

Chronic liver diseases accompanied by liver fibrosis have caused significant morbidity and mortality in the world with increasing prevalence. Nonetheless, there are no approved antifibrotic therapies. Although numerous preclinical studies showed satisfactory results in targeting fibrotic pathways, these animal studies have not led to success in humans. In this chapter, we summarize the experimental approaches currently available, including in vitro cell culture models, in vivo animal models, and new experimental tools relevant to humans, and discuss how we translate laboratory results to clinical trials. We will also address the obstacles in transitioning promising therapies from preclinical studies to human antifibrotic treatments.

Keywords: Animal models; Hepatic stellate cells; In vitro models; In vivo models; Liver fibrosis.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Animals
Fibrosis
Humans
Liver Cirrhosis* / metabolism
Liver Diseases*
Research
Workflow

Grants and funding

R01 DK085252/DK/NIDDK NIH HHS/United States